JP2018530325A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530325A5 JP2018530325A5 JP2018516525A JP2018516525A JP2018530325A5 JP 2018530325 A5 JP2018530325 A5 JP 2018530325A5 JP 2018516525 A JP2018516525 A JP 2018516525A JP 2018516525 A JP2018516525 A JP 2018516525A JP 2018530325 A5 JP2018530325 A5 JP 2018530325A5
- Authority
- JP
- Japan
- Prior art keywords
- modified oligonucleotide
- compound
- modified
- wing segment
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims description 62
- 108091034117 Oligonucleotide Proteins 0.000 claims description 56
- 239000002777 nucleoside Substances 0.000 claims description 49
- 125000003835 nucleoside group Chemical group 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 3
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 3
- 229930024421 Adenine Natural products 0.000 claims description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 2
- 229960000643 adenine Drugs 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 229940113082 thymine Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 208000019622 heart disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000001826 Marfan syndrome Diseases 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 208000015658 resistant hypertension Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021160831A JP2022008677A (ja) | 2015-10-08 | 2021-09-30 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238831P | 2015-10-08 | 2015-10-08 | |
| US62/238,831 | 2015-10-08 | ||
| PCT/US2016/056068 WO2017062816A2 (en) | 2015-10-08 | 2016-10-07 | Compounds and methods for modulating angiotensinogen expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021160831A Division JP2022008677A (ja) | 2015-10-08 | 2021-09-30 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018530325A JP2018530325A (ja) | 2018-10-18 |
| JP2018530325A5 true JP2018530325A5 (enExample) | 2020-11-05 |
Family
ID=58488579
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516525A Ceased JP2018530325A (ja) | 2015-10-08 | 2016-10-07 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
| JP2021160831A Ceased JP2022008677A (ja) | 2015-10-08 | 2021-09-30 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
| JP2023069869A Pending JP2023093644A (ja) | 2015-10-08 | 2023-04-21 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
| JP2024168190A Pending JP2025011138A (ja) | 2015-10-08 | 2024-09-27 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021160831A Ceased JP2022008677A (ja) | 2015-10-08 | 2021-09-30 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
| JP2023069869A Pending JP2023093644A (ja) | 2015-10-08 | 2023-04-21 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
| JP2024168190A Pending JP2025011138A (ja) | 2015-10-08 | 2024-09-27 | アンジオテンシノーゲンの発現を調節するための化合物及び方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10912792B2 (enExample) |
| EP (3) | EP4474389A3 (enExample) |
| JP (4) | JP2018530325A (enExample) |
| KR (3) | KR20260108184A (enExample) |
| CN (2) | CN113817735A (enExample) |
| AU (4) | AU2016334114B2 (enExample) |
| BR (2) | BR112018005223B1 (enExample) |
| CA (1) | CA2998898A1 (enExample) |
| CL (2) | CL2018000899A1 (enExample) |
| CO (1) | CO2018002598A2 (enExample) |
| HK (1) | HK1258275A1 (enExample) |
| IL (2) | IL295971A (enExample) |
| MX (2) | MX392014B (enExample) |
| MY (1) | MY200263A (enExample) |
| PE (1) | PE20181085A1 (enExample) |
| SG (1) | SG10202003148VA (enExample) |
| WO (1) | WO2017062816A2 (enExample) |
| ZA (1) | ZA201801600B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201609376SA (en) | 2014-05-22 | 2016-12-29 | Alnylam Pharmaceuticals Inc | Angiotensinogen (agt) irna compositions and methods of use thereof |
| TWI851574B (zh) | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法 |
| WO2020236755A2 (en) * | 2019-05-17 | 2020-11-26 | Ionis Pharmaceuticals, Inc. | Angiotensin ii type 1 receptor targeted oligonucleotides and uses thereof |
| IL292865A (en) * | 2019-11-13 | 2022-07-01 | Alnylam Pharmaceuticals Inc | Methods and preparations for the treatment of angiotensinogen-related disorder - (agt) |
| US11649458B2 (en) | 2020-05-05 | 2023-05-16 | University Of Kentucky Research Foundation | Inhibiting angiotensinogen to attenuate aortic pathology in Marfan syndrome |
| KR20230108728A (ko) | 2020-11-18 | 2023-07-18 | 아이오니스 파마수티컬즈, 인코포레이티드 | 앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법 |
| CN114763547A (zh) * | 2021-01-14 | 2022-07-19 | 施能康生物科技有限公司 | 靶向血管紧张素原的核酸及其用途 |
| WO2022232650A1 (en) * | 2021-04-30 | 2022-11-03 | Ionis Pharmaceuticals, Inc. | Methods for reducing agt expression |
| CA3228255A1 (en) * | 2021-08-04 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing angiotensinogen (agt) |
| US20240401045A1 (en) * | 2021-10-01 | 2024-12-05 | Adarx Pharmaceuticals, Inc. | Angiotensinogen-modulating compositions and methods of use thereof |
| CN113862268B (zh) * | 2021-10-20 | 2025-05-13 | 厦门甘宝利生物医药有限公司 | Agt抑制剂及其用途 |
| KR20240103025A9 (ko) * | 2021-11-16 | 2025-12-10 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법 |
| US20250197853A1 (en) * | 2021-11-19 | 2025-06-19 | Tuojie Biotech (Shanghai) Co., Ltd. | Sirna targeting angiotensinogen and pharmaceutical use of sirna |
| CN118541487A (zh) * | 2022-01-20 | 2024-08-23 | 上海拓界生物医药科技有限公司 | 一种dsRNA、其应用及制备方法 |
| CN117264948B (zh) * | 2022-06-14 | 2024-05-10 | 广州必贝特医药股份有限公司 | 抑制血管紧张素原基因表达的RNAi抑制剂及其应用 |
| WO2024013334A1 (en) * | 2022-07-15 | 2024-01-18 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of agt in a cell |
| US20240108741A1 (en) * | 2022-08-03 | 2024-04-04 | Sirnaomics, Inc. | COMBINATION siRNA AND PEPTIDE DOCKING VEHICLE (PDoV) COMPOSITIONS AND METHODS OF THEIR USE FOR IMPROVED REGULATION AND FUNCTIONALITY |
| EP4587573A2 (en) * | 2022-09-16 | 2025-07-23 | Sirnaomics, Inc. | Products and compositions |
| TW202430193A (zh) * | 2022-12-20 | 2024-08-01 | 美商靖因藥業（上海）有限公司 | 靶向agt之聚核酸分子及其用途 |
| CN120752336A (zh) * | 2022-12-22 | 2025-10-03 | 圣诺制药公司 | 产品和组合物 |
| CN119530218A (zh) * | 2023-08-30 | 2025-02-28 | 苏州炫景生物科技有限公司 | 双链寡核苷酸及其在抑制血管紧张素原表达中的应用 |
| CN118475697A (zh) * | 2023-05-15 | 2024-08-09 | 苏州时安生物技术有限公司 | 一种用于调节血管紧张素原基因表达的双链rna、其缀合物、药物组合物及用途 |
| JP2026520610A (ja) | 2023-06-13 | 2026-06-23 | アーナター セラピューティクス インコーポレイテッド | アンジオテンシノーゲンのための高度ｒｎａ標的化技術（ａｒｎａｔａｒ） |
| IL328055A (en) * | 2023-11-03 | 2026-06-01 | Ionis Pharmaceuticals Inc | Methods and compositions for reducing angiotensinogen |
| CN118995714B (zh) * | 2024-09-26 | 2025-12-12 | 杭州天龙药业有限公司 | 靶向抑制AGT基因表达的siRNA及其在治疗高血压中的应用 |
| WO2026108961A1 (zh) * | 2024-11-22 | 2026-05-28 | 苏州瑞博生物技术股份有限公司 | 寡核苷酸、寡核苷酸缀合物及组合物和用途 |
| WO2026133251A1 (en) | 2024-12-20 | 2026-06-25 | Novartis Ag | Combinations of antisense agents, pharmaceutical compositions and methods of use |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| WO1991006556A1 (en) | 1989-10-24 | 1991-05-16 | Gilead Sciences, Inc. | 2' modified oligonucleotides |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
| EP0455905B1 (en) | 1990-05-11 | 1998-06-17 | Microprobe Corporation | Dipsticks for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides |
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| DE59208572D1 (de) | 1991-10-17 | 1997-07-10 | Ciba Geigy Ag | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
| EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
| EP0691968B1 (en) | 1993-03-30 | 1997-07-16 | Sanofi | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| TW520293B (en) | 1995-11-22 | 2003-02-11 | Univ Johns Hopkins Med | Delivery system to enhance cellular uptake of biomolecules |
| WO1997033623A1 (en) | 1996-03-15 | 1997-09-18 | University Of Florida | OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA |
| US20080119427A1 (en) | 1996-06-06 | 2008-05-22 | Isis Pharmaceuticals, Inc. | Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| EP1015469B2 (en) | 1997-09-12 | 2015-11-18 | Exiqon A/S | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues |
| US20030228597A1 (en) | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| US6043352A (en) | 1998-08-07 | 2000-03-28 | Isis Pharmaceuticals, Inc. | 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides |
| JP2002538172A (ja) | 1999-03-05 | 2002-11-12 | ジー．ディー．サール エルエルシー | 循環器疾患治療のためのアンギオテンシン変換酵素阻害薬およびエポキシ−ステロイドアルドステロン拮抗薬の組合せ療法 |
| IL145778A0 (en) | 1999-04-21 | 2002-07-25 | American Home Prod | Methods and compositions for inhibiting the function of polynucleotide sequences |
| ATE356824T1 (de) | 1999-05-04 | 2007-04-15 | Santaris Pharma As | L-ribo-lna analoge |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| AU5016200A (en) | 1999-05-21 | 2000-12-12 | Myriad Genetics, Inc. | Diabetes gene |
| US6902888B1 (en) | 1999-05-21 | 2005-06-07 | Myriad Genetics, Inc. | Diabetes gene |
| JP2003519231A (ja) | 1999-12-30 | 2003-06-17 | カー・ユ・ルーベン・リサーチ・アンド・ディベロップメント | シクロヘキセン核酸 |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| CN100406065C (zh) | 2000-12-01 | 2008-07-30 | 细胞工厂治疗公司 | 糖基化/半乳糖基化肽、双官能接头和核苷酸单体/多聚体的缀合物以及相关的组合物和使用方法 |
| JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
| US8604183B2 (en) | 2002-11-05 | 2013-12-10 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US6673661B1 (en) | 2002-12-20 | 2004-01-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Self-aligned method for forming dual gate thin film transistor (TFT) device |
| US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
| WO2005027962A1 (en) | 2003-09-18 | 2005-03-31 | Isis Pharmaceuticals, Inc. | 4’-thionucleosides and oligomeric compounds |
| EP1799859B1 (en) | 2004-09-17 | 2014-07-02 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| WO2006047842A2 (en) | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| US20060148740A1 (en) | 2005-01-05 | 2006-07-06 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| DE602007009487D1 (de) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-modifizierte bicyclische nukleinsäureanaloga |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
| DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
| WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| EP2229186A2 (en) | 2007-12-04 | 2010-09-22 | Alnylam Pharmaceuticals Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| EP2265627A2 (en) | 2008-02-07 | 2010-12-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
| US8575123B2 (en) | 2008-04-11 | 2013-11-05 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| CN107083386A (zh) | 2008-08-25 | 2017-08-22 | 埃克斯雷德制药有限公司 | 阻止结缔组织生长因子的反义核苷酸及其用途 |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| WO2010036696A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acid analogs |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| EP2482817A1 (en) | 2009-10-01 | 2012-08-08 | Symphony Evolution, Inc. | Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors |
| WO2011139702A2 (en) | 2010-04-28 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modified nucleosides and oligomeric compounds prepared therefrom |
| EP2593099A1 (en) | 2010-07-12 | 2013-05-22 | DKFZ Deutsches Krebsforschungszentrum | Wogonin for the prevention and therapy of cardiac hypertrophy |
| US9290760B2 (en) | 2010-09-15 | 2016-03-22 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| CN102260673A (zh) * | 2011-07-12 | 2011-11-30 | 深圳职业技术学院 | 靶向人血管紧张素原的rna干扰片段、表达载体与应用 |
| US10023861B2 (en) | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| EP3693460A1 (en) * | 2012-07-27 | 2020-08-12 | Ionis Pharmaceuticals, Inc. | Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen |
| CN103103192A (zh) * | 2013-01-18 | 2013-05-15 | 深圳职业技术学院 | 靶向血管紧张素原的rna干扰片段、其表达载体、混合克隆细胞株及其应用 |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| EP2992096B1 (en) | 2013-05-01 | 2021-03-03 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
| SG11201609376SA (en) * | 2014-05-22 | 2016-12-29 | Alnylam Pharmaceuticals Inc | Angiotensinogen (agt) irna compositions and methods of use thereof |
| WO2016196111A1 (en) * | 2015-06-01 | 2016-12-08 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting angiotensinogen (agt) and methods of use thereof |
-
2016
- 2016-10-07 MX MX2018004307A patent/MX392014B/es unknown
- 2016-10-07 AU AU2016334114A patent/AU2016334114B2/en not_active Ceased
- 2016-10-07 IL IL295971A patent/IL295971A/en unknown
- 2016-10-07 JP JP2018516525A patent/JP2018530325A/ja not_active Ceased
- 2016-10-07 EP EP24190082.8A patent/EP4474389A3/en active Pending
- 2016-10-07 CA CA2998898A patent/CA2998898A1/en active Pending
- 2016-10-07 EP EP21185493.0A patent/EP3960183A1/en not_active Withdrawn
- 2016-10-07 PE PE2018000423A patent/PE20181085A1/es unknown
- 2016-10-07 BR BR112018005223-0A patent/BR112018005223B1/pt not_active IP Right Cessation
- 2016-10-07 CN CN202111106191.6A patent/CN113817735A/zh active Pending
- 2016-10-07 KR KR1020267020071A patent/KR20260108184A/ko active Pending
- 2016-10-07 SG SG10202003148VA patent/SG10202003148VA/en unknown
- 2016-10-07 CN CN201680058511.6A patent/CN108271351B/zh active Active
- 2016-10-07 KR KR1020247007192A patent/KR20240033305A/ko not_active Ceased
- 2016-10-07 MY MYPI2018701353A patent/MY200263A/en unknown
- 2016-10-07 BR BR122020023854-2A patent/BR122020023854B1/pt active IP Right Grant
- 2016-10-07 HK HK19100639.6A patent/HK1258275A1/zh unknown
- 2016-10-07 WO PCT/US2016/056068 patent/WO2017062816A2/en not_active Ceased
- 2016-10-07 US US15/763,942 patent/US10912792B2/en active Active
- 2016-10-07 EP EP16854454.2A patent/EP3359164A4/en not_active Withdrawn
- 2016-10-07 KR KR1020187012472A patent/KR20180055898A/ko not_active Abandoned
-
2018
- 2018-03-08 ZA ZA2018/01600A patent/ZA201801600B/en unknown
- 2018-03-08 IL IL257989A patent/IL257989B2/en unknown
- 2018-03-13 CO CONC2018/0002598A patent/CO2018002598A2/es unknown
- 2018-04-06 CL CL2018000899A patent/CL2018000899A1/es unknown
- 2018-04-06 MX MX2022005200A patent/MX2022005200A/es unknown
-
2020
- 2020-05-29 CL CL2020001453A patent/CL2020001453A1/es unknown
- 2020-11-23 US US17/101,299 patent/US20220000901A1/en active Pending
-
2021
- 2021-09-30 JP JP2021160831A patent/JP2022008677A/ja not_active Ceased
-
2022
- 2022-04-22 AU AU2022202671A patent/AU2022202671A1/en not_active Abandoned
-
2023
- 2023-04-21 JP JP2023069869A patent/JP2023093644A/ja active Pending
-
2024
- 2024-05-23 AU AU2024203439A patent/AU2024203439A1/en not_active Abandoned
- 2024-09-27 JP JP2024168190A patent/JP2025011138A/ja active Pending
-
2026
- 2026-07-08 AU AU2026205416A patent/AU2026205416A1/en active Pending